FDA Grants LOXO-292 Breakthrough Designation for RET Fusion-Positive Thyroid Cancer

October 15, 2018 – The FDA has granted LOXO-292 a breakthrough therapy designation for the treatment of patients with advanced RET fusion–positive thyroid cancer who require systemic therapy, have progressed on prior treatment, and have no other acceptable alternative treatment options, according to a statement from Loxo Oncology, the developer of the selective RET inhibitor. This designation supplements the two other breakthrough therapy designations … (leggi tutto)